Pharmaceutical

Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo

Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio.

Feb 19, 2025 - 06:00
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
Ono’s therapy Romvimza is administered twice-weekly compared to Daiichi Sankyo’s twice-daily Turalio.
Read the original article

Tags:

Previous Article

FDA grants fast track status to Rznomics’ RZ-001 for HCC

Next Article

Oncology and eClinical solutions: How one company is adapting to the challenges

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pharmaceutical Technology Excellence Awards 2023: Viedoc

Pharmaceutical Technology Excellence Awards 2023: Viedoc

Sep 11, 2023

Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings

Vertex secures two FDA wins for cystic fibrosis, both w...

Dec 25, 2024

STAT+: Flagship Pioneering startup lays off a third of staff

STAT+: Flagship Pioneering startup lays off a third of ...

Feb 17, 2024